Triple-negative breast cancer: are we making headway at least?
暂无分享,去创建一个
[1] H. Cunliffe,et al. Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. , 2012, Cancer letters.
[2] Tanja Fehm,et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.
[3] James A Young,et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. , 2012, The New England journal of medicine.
[4] Zhongyu Yuan,et al. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens , 2012, Medical Oncology.
[5] E. Perez,et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Roman-Roman,et al. 801 ORAL High Throughput Molecular Analyses to Select Patients for Targeted Agents , 2011 .
[7] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[8] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[9] K Miller,et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] F. Holmes,et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] F. André,et al. Biology-driven phase II trials: what is the optimal model for molecular selection? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Fabrice Andre,et al. Implications of personalized medicine—perspective from a cancer center , 2011, Nature Reviews Clinical Oncology.
[13] J. Reis-Filho,et al. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation , 2011, Modern Pathology.
[14] Mark Yoffe,et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.
[15] K. Gelmon,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[16] A. Jukkola-Vuorinen,et al. Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer , 2010 .
[17] F. Holmes,et al. Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer , 2010 .
[18] Oleksiy Tsybrovskyy,et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations , 2010, Histopathology.
[19] A. Ruíz,et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. , 2010, The New England journal of medicine.
[20] Charles M Perou,et al. Molecular stratification of triple-negative breast cancers. , 2010, The oncologist.
[21] J. Baselga,et al. Treatment of HER2-overexpressing breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] C. Denkert,et al. Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study , 2010, Breast Cancer Research and Treatment.
[23] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[24] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[25] Arlene Chan,et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Lubiński,et al. A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC). , 2010 .
[27] A. Oza,et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. , 2010 .
[28] H. Wildiers,et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. , 2010 .
[29] E. Winer,et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. , 2010 .
[30] Stephen T. C. Wong,et al. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. , 2010, European journal of cancer.
[31] D. Dearnaley,et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] E. Perez,et al. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer , 2010, Breast Cancer Research and Treatment.
[33] Z. Szallasi,et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Espié,et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. , 2010, The oncologist.
[35] J. Reis-Filho,et al. Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas) , 2010, Journal of Clinical Pathology.
[36] Rohit Bhargava,et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation , 2010, Modern Pathology.
[37] Kornelia Polyak,et al. Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer , 2010, Clinical Cancer Research.
[38] J. Lubiński,et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Hugo M. Horlings,et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.
[40] E. Winer,et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] E. Perez,et al. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. , 2009 .
[42] H. Iwata,et al. Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC). , 2009 .
[43] W. Gradishar,et al. A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC). , 2009 .
[44] D. Miles,et al. Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). , 2009 .
[45] J. Baselga,et al. SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC). , 2009 .
[46] Kum Kum Khanna,et al. Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair , 2009, Clinical Cancer Research.
[47] L. Skoog,et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] J. Testa,et al. mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary , 2009, Clinical Cancer Research.
[49] Yrjö Collan,et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors , 2009, BMC Research Notes.
[50] C. Perou,et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] A. Vincent-Salomon,et al. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum , 2009, Modern Pathology.
[52] E. Perez,et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. , 2009 .
[53] M. Campone,et al. Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies. , 2009 .
[54] Philippe Dessen,et al. Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array , 2009, Clinical Cancer Research.
[55] I. Ellis,et al. Triple‐negative/basal‐like breast cancer: review , 2009, Pathology.
[56] T. Nielsen,et al. Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] A. Luini,et al. Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity , 2009, Breast Cancer Research and Treatment.
[58] S. Narod,et al. Pattern of metastatic spread in triple-negative breast cancer , 2009, Breast Cancer Research and Treatment.
[59] Emmanuel Barillot,et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells , 2008, Breast Cancer Research.
[60] N. Lin,et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.
[61] T. Nielsen,et al. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. , 2008, Human pathology.
[62] Stephen Green,et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies , 2008, Molecular Cancer Therapeutics.
[63] S. Ashwell,et al. DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy , 2008, Clinical Cancer Research.
[64] A. Tolcher,et al. A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors , 2008 .
[65] A. Tolcher,et al. First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors , 2008 .
[66] S. Johnston,et al. Platinum-based chemotherapy in triple-negative breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[67] H. Rugo,et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[70] F. Cognetti,et al. HER2 and response to paclitaxel in node-positive breast cancer. , 2008, The New England journal of medicine.
[71] M. Sormani,et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. , 2008, Journal of the National Cancer Institute.
[72] J. Janetka,et al. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. , 2008, Expert opinion on investigational drugs.
[73] Robin L. Jones,et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.
[74] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[75] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[76] Xianglin Shi,et al. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. , 2007, Cancer research.
[77] R. Cress,et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.
[78] C. Perou,et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.
[79] L. Karnitz,et al. Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo , 2007, Cell cycle.
[80] Ian O Ellis,et al. Prognostic markers in triple‐negative breast cancer , 2007, Cancer.
[81] J. Dering,et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.
[82] B. Lloveras,et al. HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy , 2007, Journal of Cancer Research and Clinical Oncology.
[83] T. Delozier,et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] K. Gelmon,et al. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. , 2006, The oncologist.
[85] W. Gerald,et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.
[86] R. Nicholson,et al. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells , 2006, Breast Cancer Research and Treatment.
[87] A. Vincent-Salomon,et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome , 2005, Modern Pathology.
[88] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[89] V. Semiglazov,et al. Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens , 2005 .
[90] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[91] H. Lane,et al. The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.
[92] H. Lane,et al. The mTOR Inhibitor RAD 001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p 21 Translation , 2005 .
[93] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[94] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[95] Alan Mackay,et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. , 2004, Cancer research.
[96] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[97] I. Smith,et al. Neoadjuvant chemotherapy for breast cancer , 2000, Annals of medicine.
[98] G. Rijksen,et al. c‐Src PROTEIN EXPRESSION IS INCREASED IN HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSIS , 1996, The Journal of pathology.
[99] B. Asselain,et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. , 1995, European journal of cancer.